
  
    
      
        Background_NNP
        The_DT 
        in_IN vitro_NN culture_NN of_IN human_JJ peripheral_JJ
        blood_NN lymphocytes_NNS in_IN IL-_NNP 2_CD results_NNS in_IN the_DT generation_NN of_IN
        cytotoxic_JJ cells_NNS that_WDT lyse_NN tumor_NN targets_NNS ._. Natural_NNP Killer_NNP
        (_( NK_NNP )_) cells_NNS are_VBP the_DT main_JJ lymphocytic_JJ population_NN
        constitutively_RB expressing_VBG p_NN 75_CD β_NN chain_NN of_IN the_DT IL-_NNP 2_CD receptor_NN
        and_CC exhibiting_VBG up-regulation_JJ of_IN LFA-_NNP 1_CD (_( Lymphocyte_NNP Function_NNP
        associated_VBN Antigen-_NNP 1_LS )_) molecule_NN upon_IN IL-_NNP 2_CD stimulation_NN ._.
        Consequently_RB ,_, incubation_NN of_IN peripheral_JJ blood_NN lymphocytes_NNS
        with_IN IL-_NNP 2_CD induces_VBZ selective_JJ activation_NN of_IN NK_NNP cells_NNS ,_, rapid_JJ
        increase_NN of_IN NK_NNP activity_NN followed_VBN by_IN generation_NN of_IN LAK_NNP
        activity_NN and_CC proliferation_NN ._. This_DT has_VBZ been_VBN referred_VBN to_TO as_IN
        the_DT LAK_NNP phenomenon_NN [_NN 1_CD ]_NN ._. Similarly_RB IL-_NNP 12_CD treatment_NN of_IN
        peripheral_JJ blood_NN mononuclear_NN cells_NNS (_( PBMC_NNP )_) or_CC pure_JJ NK_NNP cells_NNS
        within_IN a_DT few_JJ hours_NNS ,_, induces_VBZ ,_, an_DT enhancement_NN of_IN cytotoxic_JJ
        ability_NN ._. It_PRP was_VBD observed_VBN that_IN the_DT maximum_NN enhancement_NN
        obtained_VBN with_IN IL-_NNP 12_CD is_VBZ less_JJR than_IN that_DT obtained_VBD with_IN IL-_NNP 2_CD
        and_CC comparable_JJ to_TO that_DT observed_VBD with_IN IFN-γ_NNP ._. However_RB ,_, IL-_NNP 12_CD
        was_VBD found_VBN to_TO be_VB effective_JJ at_IN concentrations_NNS 2_CD -_: 3_CD order_NN of_IN
        magnitude_NN lower_JJR than_IN IL-_NNP 2_CD /_NN IFN-γ_NNP ._. Maximum_NNP enhancement_NN of_IN NK_NNP
        mediated_JJ cytotoxicity_NN was_VBD observed_VBN with_IN a_DT combination_NN of_IN
        IL-_NNP 12_CD and_CC IL-_NNP 2_CD ,_, the_DT effect_NN of_IN the_DT two_CD cytokines_NNS together_RB
        being_VBG additive_JJ [_NN 2_CD ]_NN ._. Another_DT study_NN revealed_VBD that_DT cytokine_NN
        stimulated_VBN NK_NNP cells_NNS use_VBP both_DT granzyme_NN /_NN Fas_NNP ligand_NN pathways_NNS
        of_IN apoptotic_JJ induction_NN to_TO mediate_VB cytotoxicity_NN [_NN 3_CD ]_NN and_CC it_PRP
        was_VBD found_VBN that_IN IL-_NNP 2_CD and_CC IL-_NNP 12_CD both_DT increase_NN induction_NN in_IN
        mRNA_NN coding_VBG for_IN perforin_NN /_NN granzymes_NNS A_DT and_CC B_NNP [_NN 4_CD ]_NN ._. Hence_RB
        the_DT importance_NN of_IN both_DT these_DT cytokines_NNS in_IN enhancing_VBG
        cytotoxicity_NN cannot_NN be_VB overlooked_VBN ._.
        However_RB before_IN this_DT picture_NN about_IN the_DT involvement_NN of_IN NK_NNP
        cells_NNS in_IN LAK_NNP activity_NN emerged_VBD there_EX existed_VBD considerable_JJ
        controversy_NN regarding_VBG the_DT type_NN of_IN effector_NN cells_NNS mediating_VBG
        this_DT activity_NN ,_, particularly_RB concerning_VBG the_DT relative_JJ
        contributions_NNS by_IN the_DT two_CD lymphocyte_NN populations_NNS ,_, NK_NNP Vs_NNP
        cytotoxic_JJ T_NN cells_NNS [_NN 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN ._. Experiments_NNS in_IN which_WDT ,_,
        depletion_NN of_IN Asialo-_NNP GM_NNP (_( a_DT glycolipid_NN present_JJ on_IN the_DT surface_NN
        of_IN NK_NNP cells_NNS )_) was_VBD carried_VBN out_IN ,_, demonstrated_VBN ,_, that_IN the_DT
        generation_NN of_IN LAK_NNP cells_NNS followed_VBN by_IN IL-_NNP 2_CD stimulation_NN was_VBD
        considerably_RB reduced_VBN ,_, thereby_RB confirming_VBG that_IN the_DT NK_NNP cells_NNS
        are_VBP the_DT major_JJ contributors_NNS of_IN LAK_NNP activity_NN [_NN 10_CD ]_NN ._.
        Further_RB ,_, studies_NNS with_IN sorted_VBN pure_JJ populations_NNS of_IN CD_NNP 3_CD /_NN NK_NNP
        cells_NNS also_RB showed_VBD that_IN the_DT LAK_NNP phenomenon_NN is_VBZ predominantly_RB
        mediated_JJ by_IN IL-_NNP 2_CD activated_VBN NK_NNP cells_NNS ._. Both_DT precursor_NN and_CC
        effector_NN cells_NNS of_IN this_DT activity_NN were_VBD typically_RB NK_NNP cells_NNS [_NN
        11_CD ]_NN ._. Direct_NNP evidence_NN that_IN NK_NNP cells_NNS are_VBP the_DT mediators_NNS of_IN
        LAK_NNP activity_NN came_VBD from_IN Immunotransmission_NNP Electron_NNP
        microscopic_JJ studies_NNS using_VBG colloidal_NN gold_NN labeled_VBD antibodies_NNS
        in_IN which_WDT CD_NNP 16_CD positive_JJ cells_NNS were_VBD shown_VBN to_TO extend_VB their_PRP$
        protrusions_NNS deep_JJ into_IN the_DT target_NN cells_NNS and_CC it_PRP was_VBD found_VBN
        that_IN the_DT cytoplasmic_JJ granules_NNS and_CC vacuoles_NNS of_IN CD_NNP 16_CD positive_JJ
        LAK_NNP cells_NNS were_VBD concentrated_VBN in_IN the_DT area_NN of_IN the_DT binding_JJ site_NN
        [_NN 12_CD ]_NN ._. With_IN the_DT advent_NN of_IN flowcytometry_NN and_CC
        immunophenotyping_VBG we_PRP thought_VBD we_PRP could_MD approach_VB this_DT dilemma_NN
        in_IN a_DT different_JJ but_CC simple_JJ and_CC straightforward_JJ manner_NN ._.
        Therefore_RB we_PRP generated_VBD LAK_NNP cells_NNS by_IN the_DT method_NN of_IN Anita_NNP and_CC
        Hersh_NNP [_NN 13_CD ]_NN and_CC carried_VBD out_IN cytotoxicity_NN experiments_NNS with_IN
        the_DT stimulated_VBN cells_NNS ._. For_IN our_PRP$ cytotoxicity_NN experiments_NNS we_PRP
        used_VBD the_DT U-_NNP 937_CD cell_NN line_NN which_WDT are_VBP derived_VBN from_IN human_JJ
        histiocytic_JJ lymphoma_NN as_IN tumor_NN targets_NNS ._. U_NNP 937_CD cells_NNS share_VBP
        many_JJ surface_NN markers_NNS and_CC receptors_NNS with_IN normal_JJ human_JJ
        monocytes_NNS and_CC therefore_RB express_VB many_JJ monocyte_NN like_IN
        characteristics_NNS [_NN 14_CD 15_CD 16_CD 17_CD ]_NN ._. Concurrently_NNP we_PRP also_RB
        assessed_VBD the_DT changes_NNS in_IN the_DT phenotypic_JJ characteristics_NNS by_IN
        flowcytometry_NN ._. Flowcytometry_NNP is_VBZ a_DT powerful_JJ tool_NN that_WDT allows_VBZ
        one_CD to_TO study_VB not_RB only_RB freshly_RB isolated_VBN lymphocytes_NNS but_CC also_RB
        cells_NNS that_WDT have_VBP been_VBN cultured_JJ 
        in_IN Vitro_NNP and_CC allowed_VBN to_TO proliferate_VBP
        in_IN the_DT presence_NN of_IN stimulating_VBG factors_NNS ._. This_DT helps_VBZ to_TO
        qualitatively_RB as_RB well_RB as_RB quantitatively_RB assess_VB the_DT
        phenotypic_JJ nature_NN of_IN the_DT proliferating_VBG cells_NNS 
        in_IN Vitro_NNP ._. In_IN the_DT present_JJ study_NN our_PRP$
        aim_NN was_VBD to_TO find_VB out_RP the_DT relative_JJ contributions_NNS of_IN cells_NNS of_IN
        different_JJ phenotypes_NNS to_TO spontaneous_JJ cytotoxicity_NN and_CC study_VB
        the_DT effect_NN of_IN long_JJ term_NN 
        in_IN vitro_NN stimulation_NN of_IN cytokines_NNS on_IN
        mixed_JJ lymphocyte_NN cultures_NNS ._.
      
      
        Results_NNS
        A_DT study_NN was_VBD undertaken_VBN to_TO see_VB the_DT effect_NN of_IN IL-_NNP 2_CD and_CC /_NN or_CC
        IL-_NNP 12_CD stimulation_NN on_IN a_DT long_JJ term_NN basis_NN and_CC correlate_VBP the_DT
        phenotypic_JJ changes_NNS of_IN the_DT proliferating_VBG population_NN
        corresponding_JJ to_TO their_PRP$ cytotoxic_JJ abilities_NNS after_IN 
        in_IN vitro_NN culture_NN of_IN the_DT peripheral_JJ
        blood_NN lymphocytes_NNS ._. LAK_NNP cells_NNS were_VBD generated_VBN as_IN described_VBN ._.
        At_IN regular_JJ time_NN points_VBZ the_DT cells_NNS were_VBD harvested_VBN ._. The_DT
        chromium_NN release_NN cytotoxic_JJ assay_NN was_VBD performed_VBN by_IN the_DT
        standard_JJ procedure_NN and_CC compared_VBN with_IN the_DT corresponding_JJ
        phenotypic_JJ characteristics_NNS of_IN the_DT cells_NNS ,_, by_IN flowcytometry_NN ._.
        A_DT dot_VBP plot_NN was_VBD generated_VBN to_TO gate_NN for_IN the_DT cells_NNS after_IN
        stimulation_NN ._. A_DT representative_NN dot_VBP plot_NN of_IN unstimulated_JJ and_CC
        stimulated_VBN cells_NNS is_VBZ shown_VBN in_IN Figure_NN 1_CD ._.
        In_IN the_DT Figures_NNS 2_CD to_TO 7_CD ,_, the_DT line_NN graph_NN represents_VBZ
        percentage_NN 51_CD Cr_NNP release_NN values_NNS indicating_VBG the_DT percentage_NN NK_NNP
        cytotoxicity_NN at_IN different_JJ time_NN points_NNS in_IN response_NN to_TO
        different_JJ stimuli_NNS ._. The_DT bar_NN diagrams_NNS indicate_VBP the_DT
        corresponding_JJ phenotypic_JJ characteristics_NNS of_IN the_DT cells_NNS as_IN
        assessed_VBN by_IN flowcytometry_NN ._. The_DT total_JJ cells_NNS were_VBD analysed_JJ
        after_IN appropriately_RB applying_VBG the_DT gate_NN on_IN the_DT corresponding_JJ
        dot_VBP plots_NNS ._.
        It_PRP can_MD be_VB seen_VBN that_IN IL-_NNP 2_CD at_IN 50_CD U_NNP /_NN 10_CD 6_CD cells_NNS is_VBZ very_RB
        effective_JJ in_IN inducing_VBG proliferation_NN of_IN NK_NNP cells_NNS &_CC
        simultaneously_RB augmenting_VBG cytotoxicity_NN (_( Figure_NN 3_LS )_) ._. The_DT
        percentage_NN of_IN NK_NNP cells_NNS (_( blue_JJ bar_NN )_) rises_VBZ from_IN a_DT basal_NN value_NN
        of_IN 12_CD ±_NN 3_CD %_NN of_IN the_DT total_JJ lymphocytes_NNS on_IN day_NN zero_CD to_TO 50_CD ±_NN 5_CD
        %_NN of_IN the_DT total_JJ lymphocytes_NNS on_IN day_NN 14_CD ._. Simultaneously_RB
        percentage_NN cytotoxicity_NN (_( line_NN graph_NN )_) also_RB rises_VBZ from_IN a_DT
        basal_NN value_NN of_IN 12_CD ._. 7_CD ±_NN 4_CD ._. 2_CD %_NN on_IN day_NN zero_CD to_TO 86_CD ±_NN 7_CD ._. 1_CD %_NN on_IN
        day_NN 14_CD concurring_VBG with_IN the_DT increase_NN in_IN NK_NNP cells_NNS ._. When_WRB IL-_NNP 2_CD
        at_IN a_DT concentration_NN of_IN 50_CD U_NNP /_NN 10_CD 6_CD cells_NNS was_VBD added_VBN along_IN with_IN
        IL-_NNP 12_CD at_IN a_DT concentration_NN of_IN 125_CD U_NNP /_NN 10_CD 6_CD cells_NNS ,_, there_EX was_VBD an_DT
        increase_NN of_IN NK_NNP phenotype_NN up_IN to_TO 47_CD ±_NN 5_CD ._. 2_CD %_NN on_IN day_NN 11_CD and_CC a_DT
        corresponding_JJ maximum_NN NK_NNP activity_NN of_IN 91_CD ±_NN 6_CD ._. 5_CD %_NN (_( Figure_NN 5_LS )_) ._.
        Equally_RB impressive_JJ augmentation_NN of_IN NK_NNP activity_NN was_VBD seen_VBN
        even_RB at_IN lower_JJR concentrations_NNS of_IN IL-_NNP 2_CD and_CC IL-_NNP 12_CD in_IN
        combination_NN ._. At_IN IL-_NNP 2_CD concentration_NN of_IN 5_CD U_NNP /_NN 10_CD 6_CD cells_NNS along_IN
        with_IN IL-_NNP 12_CD concentration_NN of_IN 25_CD U_NNP /_NN 10_CD 6_CD cells_NNS ,_, there_EX was_VBD an_DT
        increase_NN of_IN NK_NNP phenotype_NN up_IN to_TO 35_CD ±_NN 3_CD ._. 1_CD %_NN on_IN day_NN 9_CD and_CC a_DT
        corresponding_JJ maximum_NN NK_NNP activity_NN of_IN 60_CD ±_NN 9_CD ._. 4_CD %_NN (_( Figure_NN 4_LS )_) ._.
        But_CC when_WRB IL-_NNP 2_CD alone_RB was_VBD added_VBN at_IN the_DT same_JJ low_JJ
        concentration_NN ,_, percentage_NN of_IN NK_NNP cells_NNS is_VBZ only_RB 9_CD ._. 4_CD ±_NN 2_CD ._. 2_CD %_NN
        on_IN day_NN 7_CD corresponding_JJ to_TO maximum_NN NK_NNP activity_NN of_IN only_RB 35_CD ±_NN
        3_CD ._. 9_CD %_NN (_( Figure_NN 2_LS )_) ._. However_RB IL-_NNP 12_CD by_IN itself_PRP at_IN concentrations_NNS
        of_IN 25_CD U_NNP or_CC 125_CD U_NNP /_NN 10_CD 6_CD cells_NNS is_VBZ unable_JJ to_TO cause_VB neither_DT an_DT
        increase_NN in_IN the_DT NK_NNP phenotype_NN nor_CC in_IN their_PRP$ cytotoxic_JJ ability_NN
        (_( Figure_NN 6_CD &_CC 7_CD )_) ._.
        From_IN Figures_NNS 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD it_PRP is_VBZ evident_JJ that_IN
        initially_RB on_IN day_NN 2_CD even_RB though_IN there_EX is_VBZ a_DT transient_JJ
        increase_NN in_IN the_DT CD_NNP 56_CD +_NN ve_NN T_NN cells_NNS (_( green_JJ bars_NNS )_) up_IN to_TO 25_CD -_: 45_CD %_NN
        the_DT corresponding_JJ increase_NN in_IN the_DT chromium_NN release_NN values_NNS
        against_IN U_NNP 937_CD target_NN cells_NNS is_VBZ negligible_JJ even_RB at_IN a_DT high_JJ dose_NN
        of_IN IL-_NNP 2_CD ._. In_IN contrast_NN ,_, at_IN later_RB time_NN points_NNS when_WRB the_DT
        cytotoxicity_NN goes_VBZ up_IN to_TO 86_CD -_: 91_CD %_NN ,_, there_EX are_VBP very_RB few_JJ CD_NNP 56_CD +_NN T_NN
        cells_NNS as_IN compared_VBN to_TO the_DT NK_NNP cell_NN phenotype_NN ._. The_DT proportion_NN
        of_IN T_NN cells_NNS (_( red_JJ bars_NNS )_) also_RB has_VBZ no_DT bearing_NN on_IN the_DT NK_NNP
        activity_NN ._.
      
      
        Discussion_NNP
        Following_VBG low_JJ dose_NN IL-_NNP 2_CD treatment_NN in_IN leprosy_NN patients_NNS ,_,
        NK_NNP cell_NN numbers_NNS were_VBD found_VBN to_TO increase_VB 6_CD -_: fold_VB and_CC IL-_NNP 2_CD
        therapy_NN of_IN HIV_NNP patients_NNS resulted_VBD in_IN enhanced_VBN NK_NNP and_CC LAK_NNP
        cell_NN activity_NN 
        in_IN vitro_NN [_NN 18_CD ]_NN IL-_NNP 2_CD subcutaneously_RB
        given_VBN resulted_VBD in_IN ,_, 
        in_IN vivo_NN expansion_NN of_IN CD_NNP 16_CD positive_JJ NK_NNP
        cells_NNS to_TO very_RB large_JJ numbers_NNS which_WDT showed_VBD LAK_NNP activity_NN and_CC
        ADCC_NNP (_( Antibody_NNP Dependent_NNP Cellular_NNP Cytotoxicity_NNP )_) 
        in_IN vitro_NN [_NN 19_CD ]_NN ._. In_IN view_NN of_IN the_DT
        above_JJ mentioned_VBN and_CC other_JJ reports_NNS available_JJ in_IN literature_NN ,_,
        a_DT pilot_NN study_NN was_VBD undertaken_VBN to_TO see_VB the_DT effect_NN of_IN IL-_NNP 2_CD
        and_CC /_NN or_CC IL-_NNP 12_CD stimulation_NN on_IN a_DT long_JJ term_NN basis_NN and_CC study_VB the_DT
        phenotypic_JJ changes_NNS corresponding_JJ to_TO the_DT cytotoxic_JJ changes_NNS
        after_IN 
        in_IN vitro_NN culture_NN of_IN the_DT peripheral_JJ
        blood_NN lymphocytes_NNS ._.
        The_DT results_NNS obtained_VBN from_IN these_DT long_JJ term_NN stimulation_NN
        studies_NNS have_VBP thrown_VBN up_RP interesting_JJ points_NNS for_IN debate_NN ._. The_DT
        phenotypic_JJ analysis_NN of_IN the_DT PBMC_NNP cultured_JJ in_IN the_DT presence_NN of_IN
        IL-_NNP 2_CD and_CC /_NN or_CC IL-_NNP 12_CD from_IN 0_CD to_TO 14_CD days_NNS has_VBZ brought_VBN to_TO light_VB
        that_IN there_EX is_VBZ a_DT gradual_JJ increase_NN in_IN the_DT percentage_NN of_IN NK_NNP
        cells_NNS suggesting_VBG that_IN these_DT cells_NNS constitute_VBP the_DT
        predominant_NN cell_NN population_NN in_IN these_DT cultures_NNS ._. This_DT
        observation_NN is_VBZ consistent_JJ with_IN the_DT results_NNS of_IN others_NNS where_WRB
        they_PRP have_VBP shown_VBN an_DT increase_NN up_IN to_TO 73_CD %_NN of_IN NK_NNP cells_NNS on_IN day_NN 9_CD
        in_IN response_NN to_TO IL-_NNP 2_CD and_CC IL-_NNP 12_CD [_NN 20_CD ]_NN ._. Even_RB at_IN low_JJ
        concentrations_NNS when_WRB IL-_NNP 2_CD is_VBZ added_VBN along_IN with_IN IL-_NNP 12_CD ,_, it_PRP is_VBZ
        able_JJ to_TO cause_VB substantial_JJ increase_NN in_IN NK_NNP cell_NN proliferation_NN
        and_CC activity_NN (_( Figure_NN 4_LS )_) comparable_JJ to_TO the_DT effect_NN seen_VBN when_WRB
        IL-_NNP 2_CD is_VBZ added_VBN alone_RB at_IN higher_JJR concentrations_NNS (_( Figure_NN 3_LS )_) ._.
        Hence_RB the_DT two_CD cytokines_NNS together_RB appear_VBP to_TO have_VB an_DT additive_JJ
        effect_NN as_IN reported_VBN by_IN other_JJ workers_NNS [_NN 21_CD ]_NN ._.
        The_DT most_RBS striking_JJ observation_NN from_IN our_PRP$ experiments_NNS is_VBZ
        that_IN it_PRP provides_VBZ clear_JJ evidence_NN that_IN the_DT "_'' CD_NNP 56_CD +_NN T_NN cells_NNS "_''
        contribute_VB little_JJ to_TO cytotoxic_JJ activity_NN against_IN the_DT U_NNP 937_CD
        target_NN cell_NN line_NN ._. It_PRP is_VBZ seen_VBN from_IN the_DT figures_NNS 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_,
        6_CD ,_, 7_CD ,_, that_IN when_WRB NK_NNP cell_NN number_NN increases_NNS ,_, the_DT NK_NNP activity_NN
        also_RB increases_VBZ ._. Initially_RB on_IN day_NN 2_CD even_RB though_IN there_EX is_VBZ a_DT
        transient_JJ increase_NN in_IN the_DT CD_NNP 56_CD +_NN T_NN cell_NN population_NN a_DT
        corresponding_JJ increase_NN in_IN the_DT chromium_NN release_NN values_NNS is_VBZ
        not_RB observed_VBN at_IN a_DT low_JJ dose_NN of_IN IL-_NNP 2_CD (_( figure_NN 2_LS )_) and_CC only_RB a_DT
        very_RB marginal_JJ increase_NN is_VBZ seen_VBN at_IN a_DT higher_JJR dose_NN of_IN IL-_NNP 2_CD
        (_( figure_NN 3_LS )_) although_IN the_DT CD_NNP 56_CD positive_JJ T_NN cells_NNS are_VBP more_RBR than_IN
        double_VB the_DT basal_NN level_NN ._. In_IN contrast_NN ,_, at_IN later_RB time_NN points_NNS
        when_WRB the_DT cytotoxicity_NN goes_VBZ up_IN to_TO 86_CD -_: 91_CD %_NN ,_, there_EX are_VBP very_RB few_JJ
        CD_NNP 56_CD positive_JJ T_NN cells_NNS as_IN compared_VBN to_TO the_DT NK_NNP cell_NN phenotype_NN
        reaffirming_VBG that_IN it_PRP is_VBZ the_DT NK_NNP phenotype_NN that_WDT is_VBZ mostly_RB
        responsible_JJ for_IN the_DT spontaneous_JJ killing_NN of_IN U-_NNP 937_CD tumor_NN
        targets_NNS ._. Similar_JJ studies_NNS have_VBP been_VBN carried_VBN out_IN using_VBG other_JJ
        tumor_NN targets_NNS such_JJ as_IN K_NNP 562_CD ,_, COLO_NNP ,_, WILMS_NNP ,_, MELANOMA_NNP and_CC P_NN 815_CD ._.
        Some_DT researchers_NNS have_VBP reported_VBN the_DT ability_NN of_IN CD_NNP 56_CD positive_JJ
        T_NN cells_NNS to_TO exhibit_VB spontaneous_JJ killing_NN against_IN some_DT of_IN the_DT
        targets_NNS such_JJ as_IN K_NNP 562_CD or_CC P_NN 815_CD ,_, upon_IN stimulation_NN with_IN IL-_NNP 2_CD [_NN
        22_CD 23_CD 24_CD 25_CD ]_NN ._. However_RB Lanier_NNP and_CC Philips_NNP who_WP carried_VBD out_IN
        extensive_JJ studies_NNS on_IN the_DT LAK_NNP phenomenon_NN have_VBP emphasised_JJ
        that_IN although_IN CD_NNP 16_CD +_NN T_NN cells_NNS exhibit_NN non-_NN MHC-restricted_NNP
        cytotoxicity_NN to_TO some_DT targets_NNS upon_IN IL-_NNP 2_CD stimulation_NN ,_, their_PRP$
        contribution_NN was_VBD quantitatively_RB and_CC qualitatively_RB very_RB
        minimal_JJ as_IN compared_VBN to_TO the_DT NK_NNP subset_NN [_NN 7_CD 11_CD ]_NN ._. The_DT
        differences_NNS in_IN the_DT ability_NN of_IN lymphocytes_NNS of_IN different_JJ
        phenotypes_NNS to_TO respond_VB to_TO IL-_NNP 2_CD stimulation_NN and_CC carry_VB out_IN
        spontaneous_JJ lysis_NNS of_IN different_JJ targets_NNS could_MD probably_RB be_VB
        attributed_VBN to_TO the_DT differential_NN expression_NN of_IN inhibitory_NN
        receptors_NNS present_JJ on_IN the_DT targets_NNS such_JJ as_IN KIR_NNP and_CC CD_NNP 94_CD :_: NKG_NNP 2_CD
        [_NN 26_CD ]_NN ._.
        Another_DT important_JJ observation_NN is_VBZ that_IN IL-_NNP 12_CD by_IN itself_PRP at_IN
        concentrations_NNS of_IN 25_CD U_NNP or_CC 125_CD U_NNP /_NN 10_CD 6_CD cells_NNS is_VBZ unable_JJ to_TO
        cause_VB neither_DT an_DT increase_NN in_IN the_DT Natural_NNP Killer_NNP phenotype_NN
        nor_CC in_IN their_PRP$ cytotoxic_JJ ability_NN (_( Figure_NN 6_CD &_CC 7_CD )_) ._. This_DT is_VBZ
        in_IN agreement_NN with_IN the_DT reported_VBN literature_NN where_WRB it_PRP has_VBZ been_VBN
        reported_VBN that_IN IL-_NNP 12_CD can_MD act_VB only_RB on_IN pre-stimulated_JJ cells_NNS
        and_CC has_VBZ little_JJ or_CC no_DT effect_NN on_IN resting_VBG lymphocytes_NNS [_NN 27_CD ]_NN ._.
        IL-_NNP 12_CD is_VBZ a_DT cytokine_NN produced_VBN to_TO some_DT degree_NN by_IN B_NNP
        lymphocytes_NNS but_CC mostly_RB by_IN phagocytic_JJ cells_NNS including_VBG
        monocytes_NNS ,_, macrophages_NNS ,_, neutrophils_NNS ,_, epidermal_NN cells_NNS ,_,
        keratinocytes_NNS and_CC dendritic_JJ cells_NNS which_WDT are_VBP among_IN the_DT first_JJ
        cells_NNS to_TO encounter_VB a_DT foreign_JJ antigen_NN during_IN infection_NN in_IN
        response_NN to_TO bacteria_NNS ,_, bacterial_JJ products_NNS ,_, intracellular_NN
        parasites_NNS ,_, etc_FW [_NN 2_CD ]_NN ._. It_PRP was_VBD found_VBN that_IN IL-_NNP 12_CD induced_VBN
        directional_NN migration_NN of_IN highly_RB enriched_JJ preparations_NNS of_IN NK_NNP
        cells_NNS and_CC CD_NNP 3_CD activated_VBN cells_NNS but_CC not_RB resting_VBG T_NN cells_NNS and_CC
        monocytes_NNS ._. When_WRB NK_NNP cells_NNS were_VBD treated_VBN overnight_JJ with_IN IL-_NNP 12_CD
        they_PRP showed_VBD augmented_JJ binding_JJ to_TO epithelial_NN cells_NNS (_( EC_NNP )_) by_IN
        the_DT LFA_NNP /_NN ICAM_NNP pathways_NNS ._. Thus_RB by_IN inducing_VBG migration_NN and_CC
        interaction_NN with_IN EC_NNP ,_, IL-_NNP 12_CD regulates_VBZ crucial_JJ determinants_NNS
        of_IN NK_NNP cell_NN recruitment_NN in_IN tissues_NNS [_NN 20_CD ]_NN ._. It_PRP is_VBZ believed_VBN
        that_IN IL-_NNP 12_CD plays_VBZ an_DT instrumental_JJ role_NN in_IN tilting_VBG the_DT immune_JJ
        response_NN in_IN favor_NN of_IN T_NN helper_NN type_NN 1_CD by_IN generation_NN of_IN Th_NNP 1_CD
        cells_NNS and_CC consequently_RB initiates_NNS CMI_NNP [_NN 28_CD ]_NN ._. Since_IN IL-_NNP 12_CD
        enhances_VBZ cytotoxicity_NN and_CC augments_NNS proliferation_NN by_IN antigen_NN
        specific_JJ T_NN cells_NNS and_CC NK_NNP cells_NNS ,_, IL-_NNP 12_CD may_MD facilitate_VB antigen_NN
        specific_JJ and_CC nonspecific_JJ cytotoxic_JJ immune_JJ defense_NN against_IN
        intracellular_NN pathogens_NNS such_JJ as_IN 
        M_NNP ._. tuberculosis_NNS ._. An_DT intriguing_JJ
        property_NN of_IN IL-_NNP 12_CD is_VBZ its_PRP$ capacity_NN to_TO induce_VB proliferation_NN
        by_IN cytolytic_JJ T_NN cell_NN only_RB upon_IN co-stimulation_JJ with_IN antigen_NN ._.
        IL-_NNP 12_CD may_MD thus_RB be_VB a_DT candidate_NN to_TO control_VB the_DT cytolytic_JJ arm_NN
        of_IN initial_JJ immune_JJ response_NN to_TO pathogens_NNS by_IN inducing_VBG
        expansion_NN of_IN cytotoxic_JJ T_NN cell_NN only_RB when_WRB antigen_NN is_VBZ
        encountered_VBN [_NN 29_CD ]_NN ._. The_DT biologic_JJ significance_NN of_IN the_DT
        multiplicity_NN of_IN cytokines_NNS which_WDT can_MD stimulate_VB the_DT
        proliferation_NN of_IN T_NN and_CC NK_NNP cells_NNS is_VBZ unclear_JJ ._. It_PRP may_MD be_VB that_IN
        the_DT various_JJ lymphokine_NN growth_NN factors_NNS are_VBP differentially_RB
        produced_VBN at_IN different_JJ time_NN points_NNS during_IN the_DT ontogeny_NN of_IN
        the_DT immune_JJ system_NN at_IN different_JJ stages_NNS in_IN the_DT development_NN of_IN
        an_DT immune_JJ response_NN or_CC at_IN different_JJ sites_NNS within_IN the_DT body_NN or_CC
        lymphoid_NN tissues_NNS [_NN 30_CD ]_NN ._. Our_PRP$ studies_NNS have_VBP confirmed_VBN the_DT
        importance_NN of_IN multiple_JJ cytokine_NN stimulation_NN of_IN lymphocytes_NNS
        and_CC how_WRB NK_NNP cells_NNS are_VBP crucial_JJ to_TO the_DT development_NN of_IN
        spontaneous_JJ cytotoxicity_NN and_CC are_VBP the_DT major_JJ contributors_NNS to_TO
        LAK_NNP activity_NN 
        in_IN vitro_NN when_WRB U-_NNP 937_CD cells_NNS were_VBD used_VBN
        as_IN targets_NNS ._. The_DT use_NN of_IN flowcytometry_NN to_TO understand_VB the_DT in_IN
        vitro_NN effects_NNS of_IN cytokine_NN stimulation_NN makes_VBZ one_CD 's_POS task_NN
        easier_JJR as_IN studies_NNS can_MD be_VB carried_VBN out_IN on_IN mixed_JJ lymphocyte_NN
        populations_NNS ._.
      
      
        Conclusions_NNP
        The_DT use_NN of_IN flowcytometry_NN as_IN a_DT tool_NN in_IN correlating_VBG the_DT
        functional_JJ capacity_NN of_IN various_JJ subpopulations_NNS of_IN mixed_JJ
        lymphocyte_NN cultures_NNS to_TO their_PRP$ phenotype_NN has_VBZ been_VBN
        demonstrated_VBN ._. A_DT study_NN was_VBD undertaken_VBN to_TO correlate_VBP the_DT
        phenotypic_JJ changes_NNS corresponding_JJ to_TO the_DT cytotoxic_JJ potential_NN
        of_IN human_JJ peripheral_JJ blood_NN lymphocytes_NNS after_IN long_JJ term_NN 
        in_IN vitro_NN stimulation_NN with_IN IL-_NNP 2_CD and_CC
        IL-_NNP 12_CD cytokines_NNS ._. As_IN reported_VBD in_IN literature_NN flowcytometric_JJ
        evidence_NN also_RB pointed_VBD to_TO the_DT fact_NN that_IN double_JJ positive_JJ
        cells_NNS constituting_VBG the_DT cytotoxic_JJ T_NN cells_NNS contribute_VBP little_JJ
        to_TO Lymphokine_NNP Activated_NNP Killer_NNP activity_NN ,_, reaffirming_VBG that_IN
        in_IN a_DT mixed_JJ lymphocyte_NN culture_NN it_PRP is_VBZ the_DT NK_NNP phenotype_NN that_WDT
        is_VBZ responsible_JJ for_IN the_DT spontaneous_JJ killing_NN of_IN tumor_NN
        targets_NNS ._. Thus_RB flowcytometry_NN can_MD be_VB easily_RB applied_VBN to_TO
        situations_NNS where_WRB one_CD needs_VBZ to_TO quickly_RB understand_VB the_DT
        phenotypic_JJ changes_NNS with_IN respect_NN to_TO their_PRP$ corresponding_JJ
        functional_JJ capacity_NN in_IN response_NN to_TO various_JJ stimulants_NNS or_CC
        inhibitory_NN agents_NNS even_RB on_IN mixed_JJ cells_NNS populations_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Media_NNP and_CC reagents_NNS
          RPMI_NNP 1640_CD culture_NN medium_NN was_VBD supplemented_JJ with_IN 5_CD %_NN heat_NN
          inactivated_JJ FCS_NNP ,_, 2_CD mM_NN glutamine_NN ,_, 5_CD mM_NN HEPES_NNP ,_, 5_CD ×_NN 10_CD -_: 5_CD M_NNP
          2_CD -_: ME_NNP ,_, 100_CD U_NNP /_NN ml_NN penicillin_NN ,_, 20_CD μg_NN /_NN ml_NN gentamycin_NN (_( pH_NN
          7_CD ._. 2_CD -_: 7_CD ._. 4_LS )_) (_( Complete_JJ medium_NN )_) ._. Ficoll_NNP hypaque_NN ,_, RPMI-_NNP 1640_CD and_CC
          all_DT other_JJ culture_NN reagents_NNS were_VBD purchased_VBN from_IN Sigma_NNP
          Chemical_NNP Co_NNP ._. ,_, St_NNP ._. Louis_NNP ,_, U_NNP ._. S_NNP ._. A_DT ._. 51_CD Chromium_NNP was_VBD obtained_VBN
          from_IN BARC_NNP ,_, Mumbai_NNP ,_, India_NNP ._. Monoclonal_NNP antibodies_NNS were_VBD
          purchased_VBN from_IN Becton_NNP and_CC Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ._. Some_DT
          of_IN the_DT monoclonal_NN antibodies_NNS were_VBD a_DT kind_NN gift_NN from_IN NIH_NNP ,_,
          Bethesda_NNP ,_, U_NNP ._. S_NNP ._. A_DT ._. U_NNP 937_CD ,_, tumor_NN target_NN cell-line_JJ was_VBD
          obtained_VBN from_IN National_NNP facility_NN for_IN animal_NN tissue_NN and_CC
          cell_NN culture_NN ,_, DBT_NNP ,_, Govt_NNP ._. ,_, of_IN India_NNP ,_, Pune_NNP ,_, India_NNP ._. rIL-_NN 2_CD
          cytokine_NN was_VBD purchased_VBN from_IN Genezyme_NNP ,_, USA_NNP and_CC rIL-_NN 12_CD
          cytokine_NN was_VBD a_DT kind_NN gift_NN from_IN Trinchieri_NNP G_NNP ,_, Philadelphia_NNP ,_,
          USA_NNP ._. All_DT plastic_NN ware_NN were_VBD obtained_VBN from_IN Costar_NNP ,_,
          Cambridge_NNP ,_, MA_NNP and_CC Falcon_NNP ,_, NJ_NNP ,_, USA_NNP ._.
        
        
          Preparation_NNP of_IN human_JJ mononuclear_NN cells_NNS
          (_( PBMC_NNP )_)
          Blood_NNP was_VBD collected_VBN from_IN 3_CD normal_JJ ,_, healthy_JJ volunteers_NNS
          in_IN heparinised_JJ containers_NNS ._. It_PRP was_VBD gently_RB layered_JJ over_IN
          equal_JJ quantities_NNS of_IN Ficoll-_NNP Hypaque_NNP density_NN gradient_NN and_CC
          centrifuged_JJ at_IN 1800_CD rpm_NN for_IN 30_CD min_NN ._. PBMC_NNP from_IN the_DT
          interface_NN were_VBD washed_VBN twice_RB in_IN Hank_NNP 's_POS Balanced_NNP Salt_NNP
          Solution_NN by_IN centrifugation_NN at_IN 1500_CD rpm_NN for_IN 15_CD min_NN ._. The_DT
          washed_VBN PBMC_NNP were_VBD suspended_VBN in_IN complete_JJ RPMI_NNP medium_NN and_CC
          adjusted_VBN to_TO a_DT volume_NN of_IN 10_CD ×_NN 10_CD 6_CD cells_NNS /_NN ml_NN ._.
        
        
          Long_JJ term_NN stimulation_NN studies_NNS
          2_LS ._. 5_CD ×_NN 10_CD 6_CD PBMCs_NNP were_VBD cultured_JJ in_IN a_DT total_JJ volume_NN of_IN 500_CD
          μl_NN complete_JJ medium_NN in_IN 48_CD -_: well_RB tissue_NN culture_NN plates_NNS in_IN
          the_DT presence_NN of_IN (_( 1_LS )_) IL-_NNP 2_CD (_( 5_CD U_NNP /_NN 10_CD 6_CD cells_NNS )_) ,_, (_( 2_LS )_) IL-_NNP 2_CD (_( 50_CD
          U_NNP /_NN 10_CD 6_CD cells_NNS )_) ,_, (_( 3_LS )_) IL-_NNP 2_CD +_NN IL-_NNP 12_CD (_( 5_CD U_NNP +_NN 25_CD U_NNP /_NN 10_CD 6_CD cells_NNS )_) ,_, (_( 4_LS )_)
          IL-_NNP 2_CD +_NN IL-_NNP 12_CD (_( 50_CD U_NNP +_NN 125_CD U_NNP /_NN 10_CD 6_CD cells_NNS )_) ,_, (_( 5_LS )_) IL-_NNP 12_CD (_( 25_CD U_NNP /_NN 10_CD
          6_CD cells_NNS )_) and_CC (_( 6_CD )_) IL-_NNP 12_CD (_( 125_CD U_NNP /_NN 10_CD 6_CD cells_NNS )_) ._. The_DT cells_NNS were_VBD
          harvested_VBN and_CC washed_VBN on_IN days_NNS 2_CD ,_, 4_CD ,_, 7_CD ,_, 9_CD ,_, 11_CD &_CC 14_CD ._.
          Chromium_NNP release_NN assay_NN was_VBD performed_VBN and_CC samples_NNS were_VBD
          also_RB analyzed_VBN by_IN flowcytometer_NN at_IN all_DT time_NN points_NNS
          including_VBG day_NN 0_CD (_( fresh_JJ PBMC_NNP )_) ._.
        
        
          Phenotyping_NNP for_IN flowcytometry_NN
          0_CD ._. 25_CD ×_NN 10_CD 6_CD cells_NNS /_NN 250_CD μl_NN medium_NN were_VBD added_VBN to_TO three_CD
          tubes_NNS and_CC 5_CD μl_NN of_IN isotype_NN control_NN ,_, leucogate_NN and_CC
          monoclonal_NN antibody_NN anti-_NN CD_NNP 3_CD PE_NNP +_NN CD_NNP 16_CD /_NN CD_NNP 56_CD FITC_NNP conjugate_NN
          was_VBD added_VBN to_TO the_DT respective_JJ tubes_NNS ._. The_DT tubes_NNS were_VBD
          incubated_JJ for_IN 15_CD min_NN at_IN 4_CD °_NN C_NNP in_IN dark_JJ and_CC washed_VBN with_IN cold_JJ
          PBS_NNP at_IN 1200_CD rpm_NN for_IN 5_CD min_NN ._. The_DT stained_JJ cells_NNS were_VBD fixed_VBN
          with_IN 0_CD ._. 5_CD ml_NN 1_CD %_NN paraformaldehyde_NN and_CC kept_VBD (_( covered_VBN with_IN
          foil_NN )_) at_IN 4_CD °_NN C_NNP until_IN further_JJ analysis_NN on_IN Flowcytometer_NNP
          (_( Becton_NNP and_CC Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP )_) using_VBG Cell_NNP Quest_NNP
          software_NN ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP analysis_NN (_( mean_VB ,_, standard_JJ deviation_NN and_CC
          graphics_NNS )_) was_VBD performed_VBN with_IN Microsoft_NNP Excel_NNP ._.
        
        
          51_CD Chromium_NNP release_NN assay_NN
          1_LS ×_NN 10_CD 6_CD target_NN U_NNP 937_CD cells_NNS in_IN 100_CD μl_NN medium_NN were_VBD
          labeled_VBN with_IN 100_CD μci_NN 51_CD Cr_NNP in_IN a_DT sterile_JJ screw-capped_JJ 4_CD ml_NN
          falcon_NN tube_NN &_CC incubated_JJ for_IN 1_CD hr_NN at_IN 37_CD °_NN C_NNP in_IN a_DT CO_NNP 
          2_CD incubator_NN ._. Target_NNP cells_NNS were_VBD then_RB
          washed_VBN twice_RB by_IN centrifugation_NN at_IN 1200_CD rpm_NN for_IN 10_CD min_NN and_CC
          suspended_VBN in_IN complete_JJ medium_NN at_IN a_DT concentration_NN of_IN 0_CD ._. 1_CD
          million_CD cells_NNS /_NN ml_NN ._. 0_CD ._. 01_CD ×_NN 10_CD 6_CD radio-labeled_JJ target_NN cells_NNS
          in_IN 100_CD μl_NN were_VBD mixed_VBN with_IN 0_CD ._. 5_CD ×_NN 10_CD 6_CD lymphocytes_NNS in_IN 50_CD μl_NN
          to_TO give_VB an_DT E_NNP :_: T_NN ratio_NN of_IN 50_CD :_: 1_CD in_IN triplicates_NNS in_IN a_DT U-_NNP bottom_NN
          96_CD -_: well_RB tissue_NN culture_NN plate_NN ._. Total_JJ volume_NN was_VBD made_VBN up_RP
          with_IN complete_JJ medium_NN and_CC adjusted_VBN to_TO 250_CD μl_NN /_NN well_RB ._. Control_NN
          wells_NNS containing_VBG only_RB target_NN cells_NNS were_VBD also_RB processed_VBN
          simultaneously_RB ._. For_IN spontaneous_JJ cytotoxicity_NN ,_, one_CD set_NN of_IN
          triplicates_NNS was_VBD set_VBN up_RP in_IN which_WDT volume_NN was_VBD adjusted_VBN to_TO
          250_CD μl_NN with_IN medium_NN alone_RB ._. In_IN another_DT set_VBN ,_, 100_CD μl_NN of_IN 1_CD %_NN
          Triton_NNP X_NNP and_CC 150_CD μl_NN medium_NN was_VBD added_VBN and_CC this_DT was_VBD
          considered_VBN as_IN maximum_NN lysis_NNS ._. The_DT 96_CD -_: well_RB plate_NN was_VBD
          centrifuged_JJ at_IN slow_JJ speed_NN (_( 1000_CD rpm_NN )_) for_IN 2_CD -_: 5_CD min_NN to_TO
          enable_VB contact_NN between_IN effectors_NNS and_CC targets_NNS ._. Incubation_NNP
          was_VBD carried_VBN out_IN for_IN 4_CD h_NN at_IN 37_CD °_NN C_NNP in_IN a_DT humidified_JJ CO_NNP 
          2_CD incubator_NN ._. Plates_NNP were_VBD then_RB
          centrifuged_JJ &_CC 150_CD μl_NN supernatant_NN was_VBD carefully_RB
          removed_VBN and_CC transferred_VBN to_TO a_DT plastic_NN vial_NN ._. Counts_NNP were_VBD
          recorded_VBN in_IN a_DT Gamma_NNP counter_NN and_CC percentage_NN cytotoxicity_NN
          was_VBD calculated_VBN as_IN follows_VBZ :_:
          
        
      
      
        List_NN of_IN abbreviations_NNS
        LAK_NNP -_: Lymphokine_NNP Activated_NNP Killer_NNP
        NK_NNP -_: Natural_NNP Killer_NNP cells_NNS ._.
        LFA-_NNP 1_CD -_: Lymphocyte_NNP Function_NNP associated_VBN Antigen_NNP ._.
        PBMC_NNP -_: Peripheral_NNP Blood_NNP Mononuclear_NNP Cells_NNP ._.
        ADCC_NNP -_: Antibody_NNP Dependent_NNP Cellular_NNP Cytotoxicity_NNP ._.
        EC_NNP -_: Epithelial_NNP Cells_NNP ._.
        ICAM_NNP -_: Ig_NNP superfamily_RB Cell_NNP Adhesion_NNP Molecule_NNP ._.
        CMI_NNP -_: Cell_NNP Mediated_NNP Immunity_NNP ._.
      
      
        Authors_NNP '_'' contributions_NNS
        R_NNP Nirmala_NNP -_: Planned_NNP and_CC executed_VBD the_DT experiments_NNS ._.
        P_NN R_NNP Narayanan_NNP -_: Designed_NNP and_CC guided_VBD the_DT studies_NNS ._.
        Both_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
